Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients

被引:14
|
作者
Martinelli, Domenico [1 ,2 ]
Tafuri, Silvio [2 ,3 ]
Caputi, Giovanni [2 ,3 ]
Fortunato, Francesca [2 ,3 ]
Reggio, Paolo [4 ]
Germinario, Cinzia [2 ,3 ]
Prato, Rosa [1 ,2 ]
机构
[1] Univ Foggia, Sez Igine, Dipartimento Sci Med & Lavoro, I-71000 Foggia, Italy
[2] Epidemiol Observ Puglia Reg, Bari, Italy
[3] Univ Bari, Sect Hyg, Dept Biomed Sci & Human Oncol, Bari, Italy
[4] Sanofi Pasteur MSD SpA, Rome, Italy
关键词
Pneumococcal 23-valent polysaccharide vaccine; invasive pneumococcal disease; vaccination coverage rate; COST-EFFECTIVENESS; OLDER-ADULTS; REVACCINATION; PNEUMONIA; DISEASE;
D O I
10.1016/j.ajic.2009.09.019
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Streptococcus pneumoniae, lancet-shaped, gram-positive, facultative anaerobic organisms, are common inhabitants of the respiratory tract and may be isolated from the nasopharynx of 5% to 70% of healthy adults. Objective: The aims of the study were to estimate the vaccination coverage for pneumococcal 23-valent polysaccharide vaccine and to assess the impact its introduction in the Italian region of Puglia, where a program to provide this vaccination has been operative since 2000. Methods: Estimation of the coverage for pneumococcal 23-valent polysaccharide vaccine was implemented by a 2-step study consisting of data collection from local health unit vaccination registers between 2000 and 2008 in Puglia and of a cluster sampling study among general practitioners to validate routine data collected during the first step. Moreover, hospitalization for invasive pneumococcal diseases was studied. Results: From 2000 to 2004, among individuals >= 65 years, the overall coverage rate estimated by routine data amounted to 26.3%; between 2005 and 2007, annual coverage rates did not exceed 8%/year. Between 2002 and 2007, the overall coverage rate estimated by interviewing general practitioners was 46.6% (95% confidence interval: 39.9-53.4). The coverage rate in chronic patients by routine data was approximately 23%, whereas the rate provided by general practitioners was 17.6% (95% confidence interval: 12.5-22.8). From 2001 to 2007, hospitalization data did not show a reduction in invasive pneumococcal disease trends among the elderly population in Puglia. Conclusion: The results of this study demonstrate the need for improving vaccine coverage and implementing new immunization strategies and practices.
引用
收藏
页码:E8 / E15
页数:8
相关论文
共 50 条
  • [41] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    VACCINE, 2013, 31 (50) : 6011 - 6021
  • [42] Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
    Sun, Xiaodong
    Tang, Yuekun
    Ma, Xiaoying
    Guo, Xiang
    Huang, Zhuoying
    Ren, Jia
    Qiu, Jing
    Jiang, Hongli
    Lu, Yihan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [43] A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
    C. R. Laratta
    K. Williams
    D. Vethanayagam
    M. Ulanova
    H. Vliagoftis
    Allergy, Asthma & Clinical Immunology, 13
  • [44] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Peterson, James T.
    Stacey, Helen L.
    MacNair, John E.
    Li, Jianing
    Hartzel, Jonathan S.
    Sterling, Tina M.
    Benner, Patrice
    Tamms, Gretchen M.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
  • [45] Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine
    Waites, Ken B.
    Canupp, Kay C.
    Chen, Yu-ying
    DeVivo, Michael J.
    Nahm, Moon H.
    JOURNAL OF SPINAL CORD MEDICINE, 2008, 31 (01) : 53 - 59
  • [46] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and previously immunized adult patients with severe chronic kidney disease
    Ulanova, Marina
    Huska, Brenda
    Desbiens, Angele
    Gaultier, Gabrielle N.
    Domonkos, Victoria
    McCready, William G.
    VACCINE, 2021, 39 (04) : 699 - 710
  • [47] Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
    Wang, Yang
    Li, Jingxin
    Wang, Yuxiao
    Gu, Wei
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (04) : 1003 - 1012
  • [48] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [49] Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy
    Lu, Ching-Lan
    Chang, Sui-Yuan
    Chuang, Yu-Chung
    Liu, Wen-Chun
    Su, Chin-Ting
    Su, Yi-Ching
    Chang, Shu-Fang
    Hung, Chien-Ching
    VACCINE, 2014, 32 (09) : 1031 - 1035
  • [50] Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases A matched case-control study
    Vila-Corcoles, Angel
    Ochoa-Gondar, Olga
    Rodriguez-Blanco, Teresa
    Gutierrez-Perez, Antonia
    Vila-Rovira, Angel
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (05) : 639 - 644